MAZE — Maze Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual balance sheet for Maze Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—
Source:	PROSPECTUS/A	PROSPECTUS/A	10-K
Standards:	USG	USG	USG
Status:	Final	Final	Final
Cash and Equivalents
Cash and Short Term Investments	99.9	29.2	197
Prepaid Expenses
Total Current Assets	106	34.1	202
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	41.2	35	29.9
Other Long Term Assets
Total Assets	150	71.5	241
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Current Liabilities	20.8	16.3	20.7
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	48.5	61.5	43.6
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Total Equity	101	10.1	197
Total Liabilities & Shareholders' Equity	150	71.5	241
Total Common Shares Outstanding
Total Preferred Shares Outstanding